Thiamine-responsive megaloblastic anemia syndrome: A Patient Guide
At a Glance
TRMA (Rogers syndrome) is an inherited SLC19A2 condition that causes megaloblastic anemia, diabetes, and sensorineural hearing loss. Lifelong high-dose oral thiamine often corrects anemia and improves blood sugar control, but may not reverse hearing loss; ongoing monitoring remains important.
Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is an ultra-rare genetic condition that fundamentally changes how the body produces and uses energy. At its core, the condition is an autosomal recessive disorder caused by a mutation in the SLC19A2 gene, which is responsible for creating a specialized “doorway” or transporter that moves thiamine (Vitamin B1) into cells [1]. When these transporters do not function correctly, vital organs—specifically the bone marrow, the pancreas, and the inner ear—become starved for thiamine, even if there is plenty of the vitamin in the diet [2].
This lack of cellular thiamine typically leads to a “classic triad” of medical challenges: megaloblastic anemia, diabetes mellitus, and sensorineural hearing loss [3]. The anemia occurs because blood cells cannot grow properly without thiamine, while the diabetes arises because the pancreas lacks the energy to produce insulin effectively [4]. The hearing loss is caused by the vulnerability of delicate cells in the inner ear to thiamine deficiency [5]. Because these symptoms can appear at different times throughout childhood, early recognition and a clear genetic diagnosis are essential for starting the right treatment [6].
The most encouraging aspect of TRMA is its responsiveness to treatment. While the body’s primary thiamine doorways are broken, giving high-dose oral thiamine allows the vitamin to enter cells through lower-affinity alternative pathways [7]. This lifelong treatment is remarkably effective at correcting the anemia and helping the body manage blood sugar levels, often reducing the need for other medications [8]. Caregivers must never self-adjust or stop thiamine doses, as strict medical supervision is critical. However, because the treatment does not always reverse established hearing loss or protect all systems equally, the focus of care is on starting thiamine early and maintaining it without interruption [9].
Living with TRMA requires a coordinated effort between a family and a multidisciplinary care team. Because the condition affects multiple parts of the body, ongoing surveillance of blood counts, blood sugar, hearing, vision, and heart health is necessary to ensure the treatment remains effective as a child grows [10].
When to seek urgent help: Families should have a clear sick-day plan. If a child with TRMA experiences severe lethargy, inability to keep medication down due to vomiting, rapid/deep breathing, or fainting, they should seek emergency medical care immediately.
While a diagnosis of an ultra-rare condition can feel overwhelming, having a named cause and a clear treatment path provides a roadmap for long-term health and stability [11]. (Note: The bracketed codes throughout this guide refer to published medical studies supporting TRMA care).
In this guide
6 chapters
Understanding a TRMA Diagnosis
Learn what a thiamine-responsive megaloblastic anemia diagnosis means for your child, including hearing, diabetes, lifelong thiamine treatment, and care planning.
Symptoms & The Classic Triad
Learn the symptoms of thiamine-responsive megaloblastic anemia syndrome, including its classic triad, early signs, and other possible health effects to monitor.
Biology, Misdiagnosis & Getting the Right Answer
Learn how SLC19A2 causes thiamine-responsive megaloblastic anemia, why TRMA mimics MDS, sideroblastic anemia, or diabetes, and how genetic testing confirms it.
High-Dose Thiamine Treatment
Learn how high-dose thiamine treats thiamine-responsive megaloblastic anemia syndrome (TRMA), including dosing, lifelong therapy, anemia and diabetes response, and monitoring.
Daily Management & Long-Term Monitoring
Learn daily care for thiamine-responsive megaloblastic anemia, including consistent thiamine, blood sugar checks, specialist monitoring, and sick-day safety.
Building Your Multidisciplinary Care Team
Learn how to build a coordinated care team for children with thiamine-responsive megaloblastic anemia, from genetic care to emergency and school planning.
Common questions in this guide
What is thiamine-responsive megaloblastic anemia syndrome?
What are the main signs of TRMA?
How does high-dose thiamine help children with TRMA?
Will thiamine treatment for TRMA need to continue for life?
What monitoring and specialists are needed for TRMA?
When should a child with TRMA receive emergency care?
Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
[Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review].
Lu H, Lu H, Vaucher J, et al.
La Revue de medecine interne 2019; (40(1)):20-27 doi:10.1016/j.revmed.2018.06.005.
PMID: 30031565 - 2
Whole exome sequencing identifies a new mutation in the SLC19A2 gene leading to thiamine-responsive megaloblastic anemia in an Egyptian family.
Amr K, Pawlikowska P, Aoufouchi S, et al.
Molecular genetics & genomic medicine 2019; (7(7)):e00777 doi:10.1002/mgg3.777.
PMID: 31144472 - 3
Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm.
Klötzer C, Schnabel F, Kubasch AS, et al.
Acta haematologica 2025; (148(4)):380-385 doi:10.1159/000542286.
PMID: 39467528 - 4
Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes.
Jungtrakoon P, Shirakawa J, Buranasupkajorn P, et al.
Diabetes 2019; (68(5)):1084-1093 doi:10.2337/db17-0821.
PMID: 30833467 - 5
Thiamine responsive megaloblastic anemia syndrome: a novel homozygous SLC19A2 gene mutation identified.
Mikstiene V, Songailiene J, Byckova J, et al.
American journal of medical genetics. Part A 2015; (167(7)):1605-9 doi:10.1002/ajmg.a.37015.
PMID: 25707023 - 6
An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.
Gurzhikhanova M, Fomenko S, Chekanov N, et al.
International journal of molecular sciences 2026; (27(14)) doi:10.3390/ijms27146274.
PMID: 42511616 - 7
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.
Habeb AM, Flanagan SE, Zulali MA, et al.
Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.
PMID: 29450569 - 8
Relapse of rare diseases during COVID-19 pandemic: bicytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.
Nouira N, Mansouri R, Tlili R, et al.
The Pan African medical journal 2020; (35(Suppl 2)):139 doi:10.11604/pamj.supp.2020.35.139.25368.
PMID: 33193954 - 9
Early thiamine therapy in Rogers syndrome: Systematic review of hematologic, auditory and glycemic outcomes.
Upadhyay Z, Sudani S, Jain A
Bioinformation 2026; (22(1)):26-30 doi:10.6026/973206300220026.
PMID: 41960466 - 10
Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives.
Tumienė B, Del Toro Riera M, Grikiniene J, et al.
Journal of multidisciplinary healthcare 2022; (15()):553-566 doi:10.2147/JMDH.S251863.
PMID: 35387391 - 11
Survey of patient satisfaction with genetic counseling services in Korea.
Choi IH, Kim YK, Yang SY, et al.
Journal of genetic counseling 2025; (34(1)):e1922 doi:10.1002/jgc4.1922.
PMID: 38769825
This page is for informational purposes only and does not constitute medical advice. The child’s treating team should guide thiamine dosing, monitoring, and urgent-care decisions.